Abstract
The initiation of the Committee for Proprietary Medicinal Products (CPMP) is set down in the EEC directive 75/319. The purpose of the CPMP is to facilitate the adoption of a common position by the member states with regard to decisions on the issuing of marketing authorizations and promoting thereby the free movements of proprietary medicinal products. The history and the functioning of the CPMP will be discussed. The development in the CPMP procedure on the first of November this year and the future trends will be presented. Special attention will be given to future steps of procedures concerning the free movements of proprietary medicinal products in Europe, not only the steps of the EEC-Commission, but also possible other steps, not yet initiated by the Commission will be discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
